Relevance of urinary interferon-gamma in the prognosis of superficial bladder cancer treated with BCG immunotherapy

被引：0
|
作者：
Zoumpos, I.
Touloupidis, S.
Giakoumelos, A.
Galaktidou, T.
Kortsaris, A.
Simopoulos, K.
Katsikas, V.
机构：
[1] Aristotle Univ Thessaloniki, Dept Urol 2, GR-54006 Thessaloniki, Greece
[2] Democritus Univ Thrace, Dept Urol, Alexandroupolis, Greece
[3] Theageneion Hosp, Dept Virol, Thessaloniki, Greece
[4] Democritus Univ Thrace, Dept Biochem, Alexandroupolis, Greece
[5] Democritus Univ Thrace, Dept Surg 2, Alexandroupolis, Greece
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2007年 / 6卷 / 02期
关键词：
D O I：
10.1016/S1569-9056(07)60494-1
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：146 / 146
页数：1
相关论文
共 50 条
  • [31] Neutrophil granulocytes play an essential role during BCG immunotherapy of superficial bladder cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (03) : 82 - 82
  • [32] BCG immunotherapy optimization on an isoperimetric optimal control problem for the treatment of superficial bladder cancer
    Elmouki I.
    Saadi S.
    International Journal of Dynamics and Control, 2016, 4 (3) : 339 - 345
  • [33] THE INHIBITORY EFFECTS OF INTERFERON-GAMMA ON THE GROWTH OF BLADDER-CANCER CELLS
    HAWKYARD, SJ
    JACKSON, AM
    JAMES, K
    PRESCOTT, S
    SMYTH, JF
    CHISHOLM, GD
    JOURNAL OF UROLOGY, 1992, 147 (05): : 1399 - 1403
  • [34] The Interferon-Gamma Paradox in Cancer
    Zaidi, M. Raza
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2019, 39 (01): : 30 - 38
  • [35] Urinary ICAM-1 levels can predict response in superficial bladder cancer treated with intravesical immunotherapy
    Zoumpos, I.
    Touloupidis, S.
    Galaktidou, T.
    Kortsaris, A.
    Simopoulos, K.
    Katsikas, V.
    EJC SUPPLEMENTS, 2005, 3 (02): : 250 - 251
  • [36] Review of BCG immunotherapy for bladder cancer
    Liatsos, George D.
    Mariolis, Ilias
    Hadziyannis, Emilia
    Bamias, Aristotelis
    Vassilopoulos, Dimitrios
    CLINICAL MICROBIOLOGY REVIEWS, 2025, 38 (01)
  • [37] Bladder Cancer Immunotherapy: BCG and Beyond
    Askeland, Eric J.
    Newton, Mark R.
    O'Donnell, Michael A.
    Luo, Yi
    ADVANCES IN UROLOGY, 2012, 2012
  • [38] Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy
    Ioannis Zachos
    Panagiotis A. Konstantinopoulos
    Gerasimos P. Vandoros
    Michalis V. Karamouzis
    Athanasios G. Papatsoris
    Thomas Podimatas
    Antonios Papachristodoulou
    Michael Chrisofos
    Charalambos Deliveliotis
    Athanasios G. Papavassiliou
    Journal of Cancer Research and Clinical Oncology, 2009, 135 : 1169 - 1175
  • [39] Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy
    Zachos, Ioannis
    Konstantinopoulos, Panagiotis A.
    Vandoros, Gerasimos P.
    Karamouzis, Michalis V.
    Papatsoris, Athanasios G.
    Podimatas, Thomas
    Papachristodoulou, Antonios
    Chrisofos, Michael
    Deliveliotis, Charalambos
    Papavassiliou, Athanasios G.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (09) : 1169 - 1175
  • [40] Generation of nitric oxide and clearance of interferon-gamma after BCG infection are impaired in mice that lack the interferon-gamma receptor
    Kamijo, R
    Gerecitano, J
    Shapiro, D
    Green, SJ
    Aguet, M
    Le, JM
    Vilcek, J
    JOURNAL OF INFLAMMATION, 1996, 46 (01) : 23 - 31
12345